VLKIM
PDLI

Van Lanschot Kempen Investment Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Van Lanschot Kempen Investment Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,506,710
Closed -$4.38M – 174
2020
Q2 		$4.38M Hold
1,506,710
– – 0.32% 88
2020
Q1 		$4.25M Sell
1,506,710
-53,757
-3% -$173K 0.35% 83
2019
Q4 		$5.06M Buy
+1,560,467
New +$4.53M 0.32% 84

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Van Lanschot Kempen Investment Management's PDLI Position: Q3 2020 in Review

Van Lanschot Kempen Investment Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 1,506,710 shares — an estimated $4.38M sold.

Van Lanschot Kempen Investment Management first reported a position in PDLI in Q4 2019 and held it in 3 quarters. The position peaked at $5.06M in Q4 2019. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • Van Lanschot Kempen Investment Management reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • Van Lanschot Kempen Investment Management sold 1,506,710 PDL BioPharma, Inc. shares in Q3 2020, an estimated $4.38M.
  • Van Lanschot Kempen Investment Management first reported a position in PDL BioPharma, Inc. in Q4 2019 and held it in 3 quarters.
  • Van Lanschot Kempen Investment Management's PDL BioPharma, Inc. position peaked at $5.06M in Q4 2019.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on Van Lanschot Kempen Investment Management's 13F filing for Q3 2020, filed 10 Nov 2020.